Bicycle Therapeutics (BCYC) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Bicycle Therapeutics faces a significant business risk due to the concentration of voting power among its existing shareholders. As of late April 2024, the Baker Entities and other key insiders collectively hold approximately 47.6% of the voting power, enabling them to substantially influence corporate decisions and potentially act in ways not aligned with the interests of other shareholders. This control may deter or prevent business combinations or changes in control that could otherwise benefit the company and its minority shareholders, possibly affecting the market price of Bicycle Therapeutics’ securities adversely.
Overall, Wall Street has a Strong Buy consensus rating on BCYC stock based on 8 Buys.
To learn more about Bicycle Therapeutics’ risk factors, click here.
